Tonix Pharmaceuticals Holding Business Update
Tonix Pharmaceuticals provided preliminary operating results for the third quarter ended September 30, 2026, estimating net revenue for TONMYA between $14.0 million and $15.0 million. The company also reported an estimated cash and cash equivalents balance of approximately $162.8 million as of quarter-end.
- Term
- Q3 2026